|
|
 |
|
Viewing report
|
|
|
|
Fulfilling the Promise of Personalized Medicine Through Next-Generation Sequencing
Decision Resources, Inc., Nov 2008, Pages: 26
The traditional pharmaceutical industry model—production of blockbuster drugs that serve many patients and generate large revenues—will give ground to the personalized medicine model, in which drugs are targeted to the patients who will benefit most. Next-generation sequencing (NGS) will be a critical, early-stage tool for companies that adopt the new model, one that will help to improve the discovery and development process and enable the development of new, high-value products.
Get the Answers You Need to Shape Your Strategy:
-Impressive technological advances have brought NGS to the fore. What companies are pioneering and commercializing NGS technologies? What are the benefits and shortcomings of current technologies? What is on the horizon for the next next-generation of sequencing technologies?
-NIH funding has been flat for several years. What alternative funding options can innovators tap?
-NGS promises to enhance drug discovery. What are the steps in this process? What is the time frame for commercialization?
Scope:
-NGS in context: data and trends that pose current challenges to R&D; pharmacogenomics; benefits of NGS.
-Personalized medicine: opportunities, challenges, trends.
-Strategic recommendations: in-house expertise and outsourcing, embracing personalized medicine, recognizing developmental time frames, partnering with diagnostics companies.
Customers who bought this item also bought
Next-Generation Genome Sequencing : Towards Personalized Medicine
Next Generation Sequencing for Life Science R&D: Advancing to the $1,000 Genome.
Next Generation Sequencing for Life Science R&D: Advancing to the $1,000 Genome
DNA Sequencing 2008
Personalized Medicine - Scientific and Commercial Aspects
DNA Sequencing - Technologies, Markets and Companies
Personalized Medicine
DNA Sequencing and PCR Markets
Next-Generation Genomic Sequencing: Market Evaluation
Companion Diagnostics in Personalized Medicine and Cancer Therapy
Biomarkers: The Future of Next-Generation Drug R&D
Cancer Personalized Medicine 2008
|
|
|
|
